1Suppliers
2Customers
2Debt Items
0Related Chains

Longeveron Inc. Suppliers

TickerNameConfidenceEvidence
THIRD-PARTY-TISSUE-SUPPLIERS THIRD-PARTY-TISSUE-SUPPLIERS 90% Fresh bone marrow is procured from established, licensed U.S.-based third-party tissue suppliers

Longeveron Inc. Customers

TickerNameConfidenceEvidence
SINGLE-CUSTOMER SINGLE-CUSTOMER 92% In both 2025 and the first quarter of 2026, the Company derived 100 % of its contract manufacturing revenue from a single customer, resulting in a significant concentration of revenue risk.
THIRD-PARTY-BIOTECHNOLOGY-COMPANY-DEVELOPING-MUL THIRD-PARTY-BIOTECHNOLOGY-COMPANY-DEVELOPING-MUL 92% On February 21, 2024, the Company entered into a five-year Supply Agreement with a third-party biotechnology company developing multiple, novel secretomes

Longeveron Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LGVN-DEBT-10697 Warrants outstanding: 0.001 90% xbrl warrant detail from xbrl 2023-12-31.
LGVN-DEBT Debt stack $748,000 90% Market cache reports total debt of $748,000.

Longeveron Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Longeveron Inc..

Longeveron Inc. Ownership

HolderNameConfidenceEvidence
LGVN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 31 tracked holders.

Longeveron Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.